Interleukin 35

Source: Wikipedia, the free encyclopedia.
"IL-35" redirects here. For the road, see Illinois Route 35.

Interleukin 35 (IL-35) is a recently discovered anti-inflammatory cytokine from the IL-12 family. Member of IL-12 family - IL-35 is produced by wide range of regulatory lymphocytes and plays a role in immune suppression.[1] IL-35 can block the development of Th1 and Th17 cells by limiting early T cell proliferation.[2]

Structure

IL-35 and its receptor

IL-35 is a dimeric protein composed of IL-12α and IL-27β chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr virus-induced gene 3), respectively.[3][4] IL-35 receptor consists of IL-12Rβ2 (part of the IL-12R) and gp130 (part of IL-27R) chains. Compared to these two related interleukins, IL-35 is also able to signal through only one of the aforementioned chains. This was proven in vivo when absence of either of the receptor chains did not influence effects of IL-35.[5] On regulatory B-cells, IL-35 signals through the IL-12Rβ2 and IL-27Rα subunits.[6]

EBI3 is a homologue to IL-12 p40 and to the ciliary neurotrophic factor receptor, whose expression is induced in B lymphoblastoid cells by EBV infection[7]

Function

Expression

Secreted by regulatory T-cells (

Bregs)[8] or even CD8+ regulatory T cells,[9] IL-35 suppresses inflammatory responses of immune cells.[10] IL-35 is not constitutively expressed in tissues, but the gene encoding IL-35 is transcribed by vascular endothelial cells, smooth muscle cells and monocytes after activation with proinflammatory stimuli.[11] IL-35 has selective activities on different T-cell subsets; it induces proliferation of Treg cell populations but reduces activity of Th17 cell populations.[12]

Role in disease

Autoimmune conditions

Studies in mice show the absence of either IL-35 chain from regulatory Tregs reduces the cells' ability to suppress inflammation. This has been observed during

Salmonella typhimurium.[8][15][16] In T1D (type 1 diabetes), plasma level of IL-35 is lower than healthy individuals. IL-35 production by Tregs is decreased in mouse models of T1D, and administration of IL-35 prevents the development of experimental T1D and reverses established experimental T1D.[17] In T1D patients with remaining C-peptide, IL-35 production by Tregs and Bregs is much higher than T1D patients with no remaining C-peptide.[18]

Infectious diseases

It has been shown that IL-35 increases replication of HBV virus both in vitro and in transgenic mice by targeting its transcription factor HNF4α.[19]

Tumor

Given its suppressive function, IL-35 is also involved in tumor progression and tumor immune surveillance.[20] Elevated circulating IL-35 levels have been found in several human tumors such as acute myeloid leukemia,[21] pancreatic ductal adenocarcinoma[22] and colorectal cancer.[23]

Moreover, Forkhead box protein 3 (

TGF-β.[24]

References

  1. PMID 27020866
    .
  2. ^
    S2CID 4425281
    .
  3. PMID 28648331
    .
  4. S2CID 19146526
    .
  5. PMID 22306691
    .
  6. PMID 24743305
    .
  7. PMID 8551575
    .
  8. ^
    PMID 24572363
    .
  9. PMID 23152566
    .
  10. PMID 29371247
    .
  11. PMID 22438968
    .
  12. S2CID 38306559
    .
  13. PMID 26922678
    .
  14. PMID 28850026
    .
  15. PMID 22814351
    .
  16. PMID 25796985
    .
  17. PMID 26224624
    .
  18. S2CID 207367998
    .
  19. PMID 29561254
    .
  20. PMID 25919641
    .
  21. PMID 22783403
    .
  22. PMID 24121041
    .
  23. PMID 24040445
    .
  24. S2CID 226218796
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Interleukin_35&oldid=1204921762"